Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

Phase 3

Completed

Conditions: Infections

Interventions: Drug: Vancomycin or Semi-Synthetic Penicillins (SSPs)
Drug: Daptomycin

First Posted Date: 2010-08-19

Last Posted Date: 2012-07-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT01184872

Locations: 🇪🇸
Novartis Investigative Site, Seville, Spain
🇷🇺
Novartis Investigative Site (2), Saint Petersburg, Russian Federation
🇪🇸
Novartis Investigative Site (1), Madrid, Spain

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Placebo to nilotinib
Drug: Nilotinib

First Posted Date: 2010-08-11

Last Posted Date: 2014-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT01179737

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling

Phase 4

Completed

Conditions: Hypertension
Left Ventricle Hypertrophy

Interventions: Drug: Aliskiren
Drug: Losartan
Drug: Amlodipine
Drug: Hydrochlorothiazide (HCTZ)

First Posted Date: 2010-08-05

Last Posted Date: 2014-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT01176032

Locations: 🇪🇸
Novartis Investigative Site, Santander, Spain

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase 2

Completed

Conditions: Dyskinesia, Drug-Induced
Levodopa
Parkinson Disease

Interventions: Drug: AFQ056

First Posted Date: 2010-08-02

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT01173731

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: imatinib mesylate

First Posted Date: 2010-07-29

Last Posted Date: 2017-05-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 132

Registration Number: NCT01172548

Locations: 🇹🇷
Novartis Investigative Site, Ankara, Turkey

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab

First Posted Date: 2010-07-29

Last Posted Date: 2014-09-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT01171976

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: AIN457A
Other: Other

First Posted Date: 2010-07-26

Last Posted Date: 2021-06-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT01169844

Locations: 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

Phase 4

Completed

Conditions: Renal Transplant

Interventions: Drug: Tacrolimus
Drug: Everolimus
Drug: Mycophenolic acid (MPA)

First Posted Date: 2010-07-26

Last Posted Date: 2015-12-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 71

Registration Number: NCT01169701

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

Completed

Conditions: Liver Diseases
Hepatitis, Chronic
Hepatitis, Viral, Human
Hepatitis
Virus Diseases
Digestive System Diseases
Hepatitis B, Chronic
Hepatitis B
DNA Virus Infections

First Posted Date: 2010-07-15

Last Posted Date: 2011-09-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1640

Registration Number: NCT01163240

Locations: 🇫🇷
Groupe Hospitalier Pellegrin - Hôpital des Enfants, Bordeaux, Aquitaine, France
🇨🇳
Henan Academy of Medical Pharmaceutical Sciences, Zhengzhou, Henan, China
🇨🇳
The Second Xiangya Hospital, Changsha, Hunan, China

and more 83 locations

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia Disorders

Interventions: Drug: AQW051 15mg (single and multiple doses)
Drug: AQW051 2 mg (single and multiple doses)
Drug: Placebo (single and multiple doses)
Drug: AQW051 100mg (single dose), and 50mg (multiple doses)

First Posted Date: 2010-07-15

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT01163227

Locations: 🇺🇸
CRI Worldwide, 1113 Hospital Dr. Suite 202,, Willingboro, New Jersey, United States
🇺🇸
PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy